Nanoparticle–allergen complexes for allergen immunotherapy

Nanoparticle–allergen complexes for allergen immunotherapy

Gabriella Di Felice,1 Paolo Colombo2 1National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, 2Institute of Biomedicine and Molecular Immunology, National Research Council, Palermo, Italy Abstract: Allergen-specific immunotherapy was introduced in clinical...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Di Felice G, Colombo P
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Allergy
Nanocarriers
Immunotoxicity
Immune modulation
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/1218e031f7c449a988a2b0d87bb07ceb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1218e031f7c449a988a2b0d87bb07ceb
record_format dspace
spelling oai:doaj.org-article:1218e031f7c449a988a2b0d87bb07ceb2021-12-02T02:31:36ZNanoparticle–allergen complexes for allergen immunotherapy1178-2013https://doaj.org/article/1218e031f7c449a988a2b0d87bb07ceb2017-06-01T00:00:00Zhttps://www.dovepress.com/nanoparticle-allergen-complexes-for-allergen-immunotherapy-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Gabriella Di Felice,1 Paolo Colombo2 1National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, 2Institute of Biomedicine and Molecular Immunology, National Research Council, Palermo, Italy Abstract: Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines. Keywords: allergy, nanocarriers, immunotoxicity, immune modulation, immunotherapy, allergensDi Felice GColombo PDove Medical PressarticleAllergyNanocarriersImmunotoxicityImmune modulationMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 4493-4504 (2017)
institution DOAJ
collection DOAJ
language EN
topic Allergy
Nanocarriers
Immunotoxicity
Immune modulation
Medicine (General)
R5-920
spellingShingle Allergy
Nanocarriers
Immunotoxicity
Immune modulation
Medicine (General)
R5-920
Di Felice G
Colombo P
Nanoparticle–allergen complexes for allergen immunotherapy
description Gabriella Di Felice,1 Paolo Colombo2 1National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, 2Institute of Biomedicine and Molecular Immunology, National Research Council, Palermo, Italy Abstract: Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines. Keywords: allergy, nanocarriers, immunotoxicity, immune modulation, immunotherapy, allergens
format article
author Di Felice G
Colombo P
author_facet Di Felice G
Colombo P
author_sort Di Felice G
title Nanoparticle–allergen complexes for allergen immunotherapy
title_short Nanoparticle–allergen complexes for allergen immunotherapy
title_full Nanoparticle–allergen complexes for allergen immunotherapy
title_fullStr Nanoparticle–allergen complexes for allergen immunotherapy
title_full_unstemmed Nanoparticle–allergen complexes for allergen immunotherapy
title_sort nanoparticle–allergen complexes for allergen immunotherapy
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/1218e031f7c449a988a2b0d87bb07ceb
work_keys_str_mv AT difeliceg nanoparticlendashallergencomplexesforallergenimmunotherapy
AT colombop nanoparticlendashallergencomplexesforallergenimmunotherapy
_version_ 1718402391273897984

Ejemplares similares